Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenpharmasecBOM:531592 -1.92%56 Gross Margin % is 9.54% as of Mar. 2026, which is 21% above its 10-year median of 7.91. GuruFocus rates BOM:531592 with a GF Score™ of 56/100 and a GF Value™ of ₹10.49 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 941 Drug Manufacturers companies, Genpharmasec ranks worse than 96.17% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genpharmasec had a gross margin of 9.54% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genpharmasec Gross Margin % Related Terms
Genpharmasec Gross Margin % Historical Data
* Premium members only.
The historical data trend for Genpharmasec's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531592 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genpharmasec's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genpharmasec Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genpharmasec's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genpharmasec's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genpharmasec (BOM:531592) has a Gross Margin % of 9.54% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Genpharmasec and its competitors. This is 21% above median its historical median of 7.91. Over the past decade, Genpharmasec's Gross Margin % has ranged from 0.17 to 20.30. According to the industry distribution chart, Genpharmasec ranks #905 out of 941 companies in the Drug Manufacturers industry, placing it in the top 96.2%.
Is Genpharmasec's Gross Margin % too high?
Genpharmasec's current Gross Margin % of 9.54% is 21% above median its 10-year median of 7.91. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 20.30. The Drug Manufacturers industry median Gross Margin % is 48.54. Genpharmasec's value of 9.54% is 80.3% below this industry median. Based on the distribution chart, Genpharmasec ranks #905 out of 941 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Genpharmasec has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genpharmasec's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genpharmasec ranks #905 out of 941 companies for Gross Margin %. This places Genpharmasec in the lower half of its industry. The industry median Gross Margin % is 48.54. Genpharmasec's value of 9.54% is 80.3% below this benchmark. Historically, Genpharmasec's own Gross Margin % has ranged from 0.17 to 20.30 over the past decade. While the company's 10-year median is 7.91 vs. the industry median of 48.54, Genpharmasec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genpharmasec's current Gross Margin % of 9.54% is 80.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genpharmasec and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genpharmasec's current Gross Margin % is 9.54%, which is 21% above median its own 10-year median of 7.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genpharmasec stock overvalued right now?
Based on GuruFocus' analysis, Genpharmasec (BOM:531592) is currently considered Possible Value Trap. The stock's GF Value™ is ₹10.49, compared to a current price of ₹1.02 — trading 90.3% below its estimated fair value. The current Gross Margin % is 9.54%, which is 21% above median its 10-year median of 7.91 and 80.3% below the Drug Manufacturers industry median of 48.54. Genpharmasec's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genpharmasec (BOM:531592), the current Gross Margin % is 9.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genpharmasec (BOM:531592) Overvalued in 2026?
Based on GuruFocus' analysis, Genpharmasec stock appears to be undervalued.
The current stock price of ₹1.02 is trading 90.3% below its estimated GF Value™ of ₹10.49.
GuruFocus considers Genpharmasec to be Possible Value Trap.
Key valuation signals for BOM:531592:
Gross Margin %: 9.54% (21% above median its 10-year median of 7.91)
GF Value™: ₹10.49 vs. price of ₹1.02 (90.3% below fair value)
Industry Position: 80.3% below the Drug Manufacturers median (#905 of 941)
No single metric tells the full story. See the BOM:531592 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genpharmasec Ltd is engaged in pharmaceutical activities and services. The company operates in three reportable segments, namely: Diagnostic Pharma Equipment, Trading in Securities, and Laboratory Testing. The company generates the majority of its revenue from the Diagnostic Pharma Equipment Segment. Geographically, the company generates the majority of its revenue from the Domestic market.
56GF Score
Get the complete analysis for BOM:531592
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531592 has been successfully added to your 
